Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
taking these steps can empower individuals to secure the treatment they need for a healthier future
Blood Tests : Regular blood tests are essential to monitor liver enzymes, kidney function, and other vital parameters
The patients treated with tirzepatide showed significantly lowered systolic and diastolic BP compared with patients in the control group, regardless of whether tirzepatide was used as a monotherapy or add-on therapy
